Actions of steroids and peptide hormones on angiogenesis

Paul J. Davis, Shaker A. Mousa, Faith B. Davis, Hung Yun Lin

研究成果: 書貢獻/報告類型章節

摘要

Levels of normal or pathologic angiogenic activity are usually considered to be products of contributions from principal vascular growth factors and their specific receptors, of anatomic locations in specific organs or, particularly in cancer, of tissue oxygen tension and of pharmaceutical modulation. In this chapter, we examine the contributions of endocrine hormones-small molecules (steroids) and peptides-to regulation of angiogenesis. Most of the hormones considered appear to have actions on blood vessels only in specific tissues, but the angiogenic properties of these substances have not been systematically studied in tissues other than those that are classical targets. Estrogens and androgens have angiogenic actions, some of which are obtained exclusively in cells obtained, respectively, from female and male sources. Estrogen and progesterone contribute to uterine angiogenesis in the menstrual cycle. Glucocorticoids that lack classical glucocorticoid activities have been designed pharmaceutically to be angiostatic drugs. Among the peptide hormones, prolactin is angiogenic in certain tissues, but the hormone is proteolytically cleaved to yield angiostatic peptides. ACTH of course affects angiogenesis in the adrenal cortex, but the ACTH receptor may be expressed in other tissues, e.g., the placenta, which then may be the focus of ACTH-dependent angiogenesis. TSH is pro-angiogenic in the thyroid gland and supports tumor-related carcinoma of the thyroid, but the TSH receptor may be expressed in other tissues and, in such settings, circulating levels of TSH may be supporting new blood vessel formation. In a separate chapter we have described the angiogenic spectrum of thyroid hormone and its analogues.
原文英語
主出版物標題Angiogenesis Modulations in Health and Disease: Practical Applications of Pro- and Anti-angiogenesis Targets
發行者Springer Netherlands
頁面47-53
頁數7
ISBN(列印)9789400764675, 9400764669, 9789400764668
DOIs
出版狀態已發佈 - 十一月 1 2013

指紋

Peptide Hormones
Steroids
Hormones
Angiostatic Proteins
Adrenocorticotropic Hormone
Glucocorticoids
Blood Vessels
Estrogens
Corticotropin Receptors
Thyrotropin Receptors
Adrenal Cortex
Menstrual Cycle
Thyroid Hormones
Thyroid Neoplasms
Pharmaceutical Preparations
Prolactin
Placenta
Androgens
Progesterone
Neoplasms

ASJC Scopus subject areas

  • Medicine(all)

引用此文

Davis, P. J., Mousa, S. A., Davis, F. B., & Lin, H. Y. (2013). Actions of steroids and peptide hormones on angiogenesis. 於 Angiogenesis Modulations in Health and Disease: Practical Applications of Pro- and Anti-angiogenesis Targets (頁 47-53). Springer Netherlands. https://doi.org/10.1007/978-94-007-6467-5_5

Actions of steroids and peptide hormones on angiogenesis. / Davis, Paul J.; Mousa, Shaker A.; Davis, Faith B.; Lin, Hung Yun.

Angiogenesis Modulations in Health and Disease: Practical Applications of Pro- and Anti-angiogenesis Targets. Springer Netherlands, 2013. p. 47-53.

研究成果: 書貢獻/報告類型章節

Davis, PJ, Mousa, SA, Davis, FB & Lin, HY 2013, Actions of steroids and peptide hormones on angiogenesis. 於 Angiogenesis Modulations in Health and Disease: Practical Applications of Pro- and Anti-angiogenesis Targets. Springer Netherlands, 頁 47-53. https://doi.org/10.1007/978-94-007-6467-5_5
Davis PJ, Mousa SA, Davis FB, Lin HY. Actions of steroids and peptide hormones on angiogenesis. 於 Angiogenesis Modulations in Health and Disease: Practical Applications of Pro- and Anti-angiogenesis Targets. Springer Netherlands. 2013. p. 47-53 https://doi.org/10.1007/978-94-007-6467-5_5
Davis, Paul J. ; Mousa, Shaker A. ; Davis, Faith B. ; Lin, Hung Yun. / Actions of steroids and peptide hormones on angiogenesis. Angiogenesis Modulations in Health and Disease: Practical Applications of Pro- and Anti-angiogenesis Targets. Springer Netherlands, 2013. 頁 47-53
@inbook{eb6ac2fc39b94493b17487dcb19b8a3e,
title = "Actions of steroids and peptide hormones on angiogenesis",
abstract = "Levels of normal or pathologic angiogenic activity are usually considered to be products of contributions from principal vascular growth factors and their specific receptors, of anatomic locations in specific organs or, particularly in cancer, of tissue oxygen tension and of pharmaceutical modulation. In this chapter, we examine the contributions of endocrine hormones-small molecules (steroids) and peptides-to regulation of angiogenesis. Most of the hormones considered appear to have actions on blood vessels only in specific tissues, but the angiogenic properties of these substances have not been systematically studied in tissues other than those that are classical targets. Estrogens and androgens have angiogenic actions, some of which are obtained exclusively in cells obtained, respectively, from female and male sources. Estrogen and progesterone contribute to uterine angiogenesis in the menstrual cycle. Glucocorticoids that lack classical glucocorticoid activities have been designed pharmaceutically to be angiostatic drugs. Among the peptide hormones, prolactin is angiogenic in certain tissues, but the hormone is proteolytically cleaved to yield angiostatic peptides. ACTH of course affects angiogenesis in the adrenal cortex, but the ACTH receptor may be expressed in other tissues, e.g., the placenta, which then may be the focus of ACTH-dependent angiogenesis. TSH is pro-angiogenic in the thyroid gland and supports tumor-related carcinoma of the thyroid, but the TSH receptor may be expressed in other tissues and, in such settings, circulating levels of TSH may be supporting new blood vessel formation. In a separate chapter we have described the angiogenic spectrum of thyroid hormone and its analogues.",
author = "Davis, {Paul J.} and Mousa, {Shaker A.} and Davis, {Faith B.} and Lin, {Hung Yun}",
year = "2013",
month = "11",
day = "1",
doi = "10.1007/978-94-007-6467-5_5",
language = "English",
isbn = "9789400764675",
pages = "47--53",
booktitle = "Angiogenesis Modulations in Health and Disease: Practical Applications of Pro- and Anti-angiogenesis Targets",
publisher = "Springer Netherlands",

}

TY - CHAP

T1 - Actions of steroids and peptide hormones on angiogenesis

AU - Davis, Paul J.

AU - Mousa, Shaker A.

AU - Davis, Faith B.

AU - Lin, Hung Yun

PY - 2013/11/1

Y1 - 2013/11/1

N2 - Levels of normal or pathologic angiogenic activity are usually considered to be products of contributions from principal vascular growth factors and their specific receptors, of anatomic locations in specific organs or, particularly in cancer, of tissue oxygen tension and of pharmaceutical modulation. In this chapter, we examine the contributions of endocrine hormones-small molecules (steroids) and peptides-to regulation of angiogenesis. Most of the hormones considered appear to have actions on blood vessels only in specific tissues, but the angiogenic properties of these substances have not been systematically studied in tissues other than those that are classical targets. Estrogens and androgens have angiogenic actions, some of which are obtained exclusively in cells obtained, respectively, from female and male sources. Estrogen and progesterone contribute to uterine angiogenesis in the menstrual cycle. Glucocorticoids that lack classical glucocorticoid activities have been designed pharmaceutically to be angiostatic drugs. Among the peptide hormones, prolactin is angiogenic in certain tissues, but the hormone is proteolytically cleaved to yield angiostatic peptides. ACTH of course affects angiogenesis in the adrenal cortex, but the ACTH receptor may be expressed in other tissues, e.g., the placenta, which then may be the focus of ACTH-dependent angiogenesis. TSH is pro-angiogenic in the thyroid gland and supports tumor-related carcinoma of the thyroid, but the TSH receptor may be expressed in other tissues and, in such settings, circulating levels of TSH may be supporting new blood vessel formation. In a separate chapter we have described the angiogenic spectrum of thyroid hormone and its analogues.

AB - Levels of normal or pathologic angiogenic activity are usually considered to be products of contributions from principal vascular growth factors and their specific receptors, of anatomic locations in specific organs or, particularly in cancer, of tissue oxygen tension and of pharmaceutical modulation. In this chapter, we examine the contributions of endocrine hormones-small molecules (steroids) and peptides-to regulation of angiogenesis. Most of the hormones considered appear to have actions on blood vessels only in specific tissues, but the angiogenic properties of these substances have not been systematically studied in tissues other than those that are classical targets. Estrogens and androgens have angiogenic actions, some of which are obtained exclusively in cells obtained, respectively, from female and male sources. Estrogen and progesterone contribute to uterine angiogenesis in the menstrual cycle. Glucocorticoids that lack classical glucocorticoid activities have been designed pharmaceutically to be angiostatic drugs. Among the peptide hormones, prolactin is angiogenic in certain tissues, but the hormone is proteolytically cleaved to yield angiostatic peptides. ACTH of course affects angiogenesis in the adrenal cortex, but the ACTH receptor may be expressed in other tissues, e.g., the placenta, which then may be the focus of ACTH-dependent angiogenesis. TSH is pro-angiogenic in the thyroid gland and supports tumor-related carcinoma of the thyroid, but the TSH receptor may be expressed in other tissues and, in such settings, circulating levels of TSH may be supporting new blood vessel formation. In a separate chapter we have described the angiogenic spectrum of thyroid hormone and its analogues.

UR - http://www.scopus.com/inward/record.url?scp=84931350736&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84931350736&partnerID=8YFLogxK

U2 - 10.1007/978-94-007-6467-5_5

DO - 10.1007/978-94-007-6467-5_5

M3 - Chapter

AN - SCOPUS:84931350736

SN - 9789400764675

SN - 9400764669

SN - 9789400764668

SP - 47

EP - 53

BT - Angiogenesis Modulations in Health and Disease: Practical Applications of Pro- and Anti-angiogenesis Targets

PB - Springer Netherlands

ER -